In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Analysts have recently evaluated Eli Lilly and Co and provided 12-month price targets. The average target is $930.96, accompanied by a high estimate of $1025.00 and a low estimate of $840.00.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, ... Our analyst team just revealed what they believe are the 10 best stocks to buy right now.

Eli Lilly To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday. Story by Avi Kapoor • 4w. T op Wall Street analysts changed their outlook on these top names.

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall within a range of $13.02 and $13.52 (the previous forecast was $16.10 to ...

Eli Lilly (NYSE:LLY) has been in the spotlight recently with a 3.96% share price increase over the past month. The selection ...

Eli Lilly and Company (NYSE:LLY – Free Report) – Stock analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Eli Lilly and Company in a research note issued on ...

Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...

Analysts surveyed by FactSet expected $13.93 billion. Eli Lilly expects 2025 revenue between $58 billion and $61 billion. The company sees 2024 revenue around $45 billion, 32% above sales from the ...

Here's what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $3.34 adjusted vs. $3.02 expected ...

Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00.

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...